In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
AUTOR(ES)
Eliopoulos, G M
RESUMO
The in vitro activity of the fluoroquinolone CP-99,219 against gram-positive bacteria was compared with those of five other antimicrobial agents. Against ciprofloxacin-susceptible staphylococci and against streptococci, MICs were < or = 0.12 and < or = 0.5 microgram/ml, respectively. CP-99,219 was also more active than ciprofloxacin against ciprofloxacin-resistant staphylococci, most enterococci, Leuconostoc spp., and lactobacilli.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=187672Documentos Relacionados
- In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae.
- In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.
- Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
- In vitro activity of the new fluoroquinolone CP-99,219.
- Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
